Max Verstappen has become just the fifth driver in Formula 1 history to clinch the world title on a Saturday – and the first in 40 years. The Dutchman, who has won every grand prix bar three this season, sealed his third straight world title after Sergio Perez crashed in the sprint race at the Qatar Grand Prix on Saturday, leaving his team-mate nable to catch him with six races and two sprints to go. Verstappen has been unstoppable throughout 2023 and, despite his dislike of the sprint race format, secured his 2023 crown in the 100km dash around the Lusail International Circuit on Saturday night. It marks the end of a streak dating back to 1983 of drivers clinching the world title on a Sunday, the traditional day of a grand prix race. The last title-clincher on a Saturday was Nelson Piquet in 1983, who won the championship at the season finale in South Africa – with the grand prix held at Kyalami on a Saturday. The two previous winners – Piquet in 1981 and Keke Rosberg in 1982 – also claimed the title on a Saturday, with both seasons concluding at the Caesars Palace Grand Prix in Las Vegas, held on a Saturday. Prior to that, British driver Graham Hill secured the 1962 world title at the South African Grand Prix in East London, again on a Saturday. And 1959 champion Jack Brabham sealed his moment of victory on a Saturday too, at the United States Grand Prix, then held in Sebring, Florida. Saturday night racing, as well as the six sprint races this season, is making a return for a full grand prix next month as Las Vegas hosts the highly-anticipated street race on the famous strip at 10pm local time on Saturday 18 November. The 2024 season will also start with two Saturday night races – in Bahrain and Saudi Arabia – due to Ramadan. Sunday is considered a “feast day” during the Islamic festival, which sees the world’s almost two-billion Muslims fast between sunrise and sunset during the other six days of the week. Read More Piastri takes first F1 pole for Qatar sprint as Verstappen starts third F1 Qatar Grand Prix LIVE: Sprint race updates and results at Lusail Lance Stroll shoves personal trainer and gives furious seven-word interview in Qatar

Ed Atkins holds a basket filled with small, wriggling shrimp, fresh examples of the catch that the African-American fisherman has drawn from the waters off South Carolina's Saint Helena...

Amazon Web Services (AWS) launched a small cube computer that's cheaper than a laptop while

Taking 100mg of aspirin every day could lower the risk of people aged 65 and over developing type 2 diabetes, researchers have suggested. Scientists – led by Professor Sophia Zoungas of Monash University’s School of Public Health and Preventive Medicine in Melbourne – said their findings warrant further exploration but do not change the current clinical guidelines on older people taking aspirin. Some 16,209 people were included in the study; 8,086 were given aspirin while 8,123 were given a placebo. All were aged 65 or over and did not suffer from cardiovascular disease, physical disabilities or dementia. Although these new findings are of interest, they do not change the clinical advice about aspirin use in older people at this time Prof Zoungas Over a median follow-up of 4.7 years, researchers found the group given aspirin had a 15% reduction in type 2 diabetes and a slower rate of increase in fasting plasma glucose (FPG) levels. The authors said: “Given the increasing prevalence of type 2 diabetes among older adults, the potential for anti-inflammatory agents like aspirin to prevent type 2 diabetes or improve glucose levels needs further study.” The findings will be presented to delegates at the annual meeting of the European Association for the Study of Diabetes (EASD) in Hamburg in October. However, the study was a follow-up of the ASPREE trial, which was published in 2018. It found taking aspirin led to a 38% increased risk of major haemorrhage in older adults without any reduction in incidence of cardiovascular disease. Prof Zoungas said her team’s research does “not change clinical advice” around older people taking aspirin. According to the NHS, a low-dose of aspirin – 75mg – each day can help to prevent heart attacks and strokes in people who are at high risk of them, but should only be taken if your doctor recommends it. Prof Zoungas added: “The earlier published trial findings from ASPREE in 2018 showed aspirin did not prolong healthy independent living, but was associated with a significantly increased risk of bleeding, primarily in the gastrointestinal tract. “Major prescribing guidelines now recommend older adults take daily aspirin only when there is a medical reason to do so, such as after a heart attack. “Although these new findings are of interest, they do not change the clinical advice about aspirin use in older people at this time.” In June, a paper published in The Lancet Diabetes and Endocrinology journal claimed 1.3 billion people could be living with diabetes by 2050 – more than double the 529 million cases in 2021. Academics described the condition as one of the “biggest public health threats of our time”. However, Dr Faye Riley, research communications manager at Diabetes UK, said the link between aspirin and diabetes prevention “remains unclear”. She added: “With more than 2.4 million people in the UK at high risk of type 2 diabetes, there’s an urgent need to find new and better ways to help people avoid the condition. “While this research found that taking a daily low-dose aspirin was linked to a small decrease in risk of type 2 diabetes in older people, whether aspirin has a role to play in type 2 prevention remains unclear, and this approach may have unwanted side effects. “We know the use of daily aspirin increases risk of potentially serious bleeding in people with diabetes and others, so we advise only taking daily low-dose aspirin if your doctor recommends it and they will discuss exactly what dose is right for you. “We do know the best ways to reduce your risk of type 2 are getting support to lose weight if you need to, eating a healthy, balanced diet and doing more physical activity. “ Read More Charity boss speaks out over ‘traumatic’ encounter with royal aide Ukraine war’s heaviest fight rages in east - follow live Secondhand September: The best places to buy pre-loved fashion online What are gynaecological cancers and how can you prevent them? Alzheimer’s: How and when to talk to someone about their memory loss

BOSTON--(BUSINESS WIRE)--Aug 14, 2023--

I love white clothes. My closet is so packed with white button downs, dresses, and linen skirts that I’m starting to worry I won’t have enough non-white options to wear on a friend’s upcoming bachelorette trip. My nails, however, are a different story. Most white nail polishes make me think of Wite-Out or glow-in-the-dark paint — not exactly in line with the clean aesthetic my mostly white wardrobe evokes.

When you think of the hoity-toity world of luxury fragrance, the iconic perfume maisons in France may come to mind first. However, Glasshouse Fragrances is putting Australia on the map in a major way — and while I wasn’t expecting it, I’m extremely here for it.

TONGYEONG, South Korea--(BUSINESS WIRE)--Jun 26, 2023--

Alcohol addiction ruins millions of lives every year, but scientists may have found a cure for this terrible affliction. A new treatment for alcohol use disorder (AUD) has been trialled in monkeys with impressive results and, if these translate to human trials, the impact could be monumental. A team of neuroscientists and physiologists from across the US tested a new type of gene therapy to see if they could directly target the underlying brain circuitry associated with sustained heavy drinking. As they noted, in the journal Nature Medicine, people suffering from AUD commonly return to alcohol use even if they attempt to quit. This is largely to do with what’s known as mesolimbic dopamine (DA) signalling – meaning how the central nervous system circuit communicates the feelgood neurotransmitter dopamine. A protein called glial-derived neurotrophic factor (GDNF) is key to keeping these neurons in this reward circuitry functioning. However, experts have found that levels of GDNF are reduced in people with AUD during periods of alcohol abstinence, most notably in a region of the brain called the ventral tegmental area (VTA), as IFLScience notes. Therefore, the researchers decided to test whether using gene therapy to deliver more GDNF to the VTA could help reinforce this crucial dopaminergic signalling and prevent patients from suffering an alcoholic relapse. The team of scientists explained how alcohol consumption in non-addicts prompts the release of dopamine, creating a pleasurable buzz feeling, but chronic alcohol use causes the brain to adapt and stop releasing so much dopamine. “So when people are addicted to alcohol, they don’t really feel more pleasure in drinking,” Dr Kathleen Grant, a senior co-author of the study, said in a statement. “It seems that they’re drinking more because they feel a need to maintain an intoxicated state.” For their research, Dr Grant and her colleagues used eight rhesus macaque monkeys, who were exposed to increasing concentrations of alcohol over four 30-day “induction” periods. The monkeys then had free access to alcohol and water for 21 hours a day for six months, during which they developed heavy drinking behaviours. This was then followed by a 12-week abstinence phase, with the GDNF treatment performed four weeks in for half of the subjects. The gene therapy was delivered using a a viral vector containing a copy of the human GDNF gene injected directly into the primate’s VTA, according to IFLScience. And the results were truly jaw-dropping. “Drinking went down to almost zero,” Dr Grant said. “For months on end, these animals would choose to drink water and just avoid drinking alcohol altogether. They decreased their drinking to the point that it was so low we didn’t record a blood-alcohol level.” The most exciting aspect of their findings is the suggestion that gene therapy could offer a permanent solution for people with the most severe cases of AUD. This will be a welcome glimmer of hope to many, given that some 29.5 million people were diagnosed with AUD in the US alone in 2021, according to the National Institute on Alcohol Abuse and Alcoholism. Of these 29.5 million sufferers, almost a million (894,000) were aged between 12 and 17. It’ll likely be some time before we know for sure whether the gene therapy can be rolled out in humans, but it’s an important first step in tackling this devastating disorder. Sign up for our free Indy100 weekly newsletter Have your say in our news democracy. Click the upvote icon at the top of the page to help raise this article through the indy100 rankings.

Spotify Technology SA is planning a more expensive subscription option that’s expected to include high-fidelity audio in an

TL;DR: As of August 24, you can get the Lenovo IdeaPad 11.6" HD Intel N4020

TL;DR: Find a wide range of free Python courses on Udemy. Learn at your own